Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?

Authors

Jasmine A. Luzum
David Lanfear, Henry Ford HealthFollow

Recommended Citation

Luzum JA, Lanfear DE. Pharmacogenetic risk scores for perindopril clinical and cost effectiveness in stable coronary artery disease: When are we ready to implement? J Am Heart Assoc. Mar 2016;5(3):e003440.

Document Type

Article

Publication Date

3-28-2016

Publication Title

J Am Heart Assoc

Comments

© authors, original version available at: 10.1161/JAHA.116.003440

Creative Commons Attribution Non-Commercial License

Medical Subject Headings

Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Perindopril; Pharmacogenetics

PubMed ID

27021567

Volume

5

Issue

3

First Page

003440

Last Page

003440